{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T23:33:35Z","timestamp":1722468815817},"reference-count":25,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T00:00:00Z","timestamp":1417478400000},"content-version":"unspecified","delay-in-days":2406,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. j. neurol. sci."],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:sec id=\"S0317167100008593_abs1\"><jats:title><jats:bold><jats:italic>Introduction:<\/jats:italic><\/jats:bold><\/jats:title><jats:p>Pergolide is an ergot derived dopamine agonist that is widely used for the treatment of Parkinson\u2019s disease. Studies have found an association between pergolide and valvular heart abnormalities although there is still much to be learned about the clinical significance of the valvular changes, who is at risk, and whether there is duration of exposure effect.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100008593_abs2\"><jats:title><jats:bold><jats:italic>Objective:<\/jats:italic><\/jats:bold><\/jats:title><jats:p>To assess the long term risk of hospital admissions for valvular heart disease (VHD) or congestive heart failure (CHF, a clinically overt outcome of VHD) in new users of pergolide compared to new users of levodopa. The secondary objective was to assess whether there are any characteristics that can predict who is at higher risk of developing this outcome.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100008593_abs3\"><jats:title><jats:bold><jats:italic>Design:<\/jats:italic><\/jats:bold><\/jats:title><jats:p>Retrospective, population-based cohort study.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100008593_abs4\"><jats:title><jats:bold><jats:italic>Setting:<\/jats:italic><\/jats:bold><\/jats:title><jats:p>Ontario, Canada.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100008593_abs5\"><jats:title><jats:bold><jats:italic>Subjects:<\/jats:italic><\/jats:bold><\/jats:title><jats:p>Ontario residents aged 66 and older, newly started on treatment with either pergolide or levodopa.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100008593_abs6\"><jats:title><jats:bold><jats:italic>Outcomes:<\/jats:italic><\/jats:bold><\/jats:title><jats:p>Admission to hospital with the most responsible diagnosis of congestive heart failure or valvular heart disease.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100008593_abs7\"><jats:title><jats:bold><jats:italic>Results:<\/jats:italic><\/jats:bold><\/jats:title><jats:p>The risk for admission for valvular heart disease or congestive heart failure were higher in those with 1-4 years exposure to pergolide compared with no exposure to pergolide (VHD: hazard ratio 2.4, p = 0.04; CHF: hazard ratio 1.6, p =0.02). No such pattern was found with exposure to levodopa.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100008593_abs8\"><jats:title><jats:bold><jats:italic>Conclusion:<\/jats:italic><\/jats:bold><\/jats:title><jats:p>Our study demonstrates that treatment with pergolide is associated with a higher risk of hospital admission for valvular heart disease or congestive heart failure and that this risk is greater in those with 1-4 years exposure than in those with less exposure. We did not find an increased risk beyond four years.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s0317167100008593","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T15:17:26Z","timestamp":1418397446000},"page":"173-178","source":"Crossref","is-referenced-by-count":10,"title":["Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative Data"],"prefix":"10.1017","volume":"35","author":[{"given":"Cindy","family":"Zadikoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh","family":"Duong-Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Sykora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie","family":"Marras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Rochon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,12,2]]},"reference":[{"key":"S0317167100008593_ref020","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"S0317167100008593_ref015","doi-asserted-by":"publisher","DOI":"10.4065\/80.8.1016"},{"key":"S0317167100008593_ref017","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15945-X"},{"key":"S0317167100008593_ref001","first-page":"235","article-title":"Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature","volume":"5","author":"Hendrikx","year":"1996","journal-title":"J Heart Valve Dis"},{"key":"S0317167100008593_ref004","doi-asserted-by":"publisher","DOI":"10.4065\/77.12.1280"},{"key":"S0317167100008593_ref024","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062222"},{"key":"S0317167100008593_ref019","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200502000-00012"},{"key":"S0317167100008593_ref016","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100004650"},{"key":"S0317167100008593_ref011","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000083985.00343.F2"},{"key":"S0317167100008593_ref013","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000129842.49926.07"},{"key":"S0317167100008593_ref002","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-1-50"},{"key":"S0317167100008593_ref014","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20887"},{"key":"S0317167100008593_ref007","unstructured":"Pergolide pulled from market. 2007. http:\/\/www.fda.gov\/cder\/drug\/advisory\/pergolide.htm"},{"key":"S0317167100008593_ref025","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)01064-9"},{"key":"S0317167100008593_ref006","unstructured":"Health Canada Warning. http:\/\/www.hc-sc.gc.ca\/dhp-mps\/medeff\/advisories-avis\/prof\/2004\/shire_permax_hpc-cps_e.html"},{"key":"S0317167100008593_ref012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054830"},{"key":"S0317167100008593_ref003","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(96)90544-X"},{"key":"S0317167100008593_ref010","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.039867"},{"key":"S0317167100008593_ref005","unstructured":"Pergolide mesilate: strengthened warning. WHO Drug Information v17il, 37.2003."},{"key":"S0317167100008593_ref021","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.492033"},{"key":"S0317167100008593_ref022","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/154.9.854"},{"key":"S0317167100008593_ref008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"S0317167100008593_ref009","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.4.790"},{"key":"S0317167100008593_ref018","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20931"},{"key":"S0317167100008593_ref023","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167100008593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T23:56:52Z","timestamp":1556668612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167100008593\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0317167100008593"],"URL":"https:\/\/doi.org\/10.1017\/s0317167100008593","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}